Highlights of This Issue 4417

SPECIAL FEATURES

CCR Translations

4419 TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal
Ramaswamy Govindan and Jason Weber
See related article, p. 4647

4422 “Companion Diagnostics”: Has Their Time Come and Gone?
Fred R. Hirsch, Paul A. Bunn Jr, and Roy S. Herbst
See related article, p. 4488

CCR New Strategies

4425 New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
Juliane M. Jürgensmeier, Joseph P. Eder, and Roy S. Herbst

CCR Perspectives in Drug Approval

4436 FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Molecular Pathways

4442 Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Felix Y. Feng, J. Chad Brenner, Maha Hussain, and Arul M. Chinnaiyan

CANCER THERAPY: CLINICAL

4449 Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

4459 p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
Nicola R. Hardwick, Mary Carroll, Teodora Kalcheva, Dajun Qian, Dean Lim, Lucille Leong, Peiguo Chu, Joseph Kim, Joseph Chao, Maryvan Fakih, Yun Yun, Jonathan Espenschied, Joshua D.L. Ellenhorn, Don J. Diamond, and Vincent Chung

4471 Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients
Jacques Medioni, Gael Deplanque, Jean-Marc Ferrero, Tristan Maurerina, Jean-Michel P. Rodier, Eric Raymond, Jorge Allyon, Gerard Maruani, Pascal Houver, Sarah Mackenzie, Stephanie Renaux, Jean-Francois Dufour-Lamartine, Reza Elaidi, Celine Lerest, and Stephane Oudard

PERSONALIZED MEDICINE AND IMAGING

4478 Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non-Small Cell Lung Cancer
Christiane Amendt, Eike Staub, Manja Friese-Hamim, Stephan Stökel, and Christopher Stroh

4488 Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
See related commentary, p. 4422
ABOUT THE COVER

The cover shows the crystal structure of the SAR650984-Fab in complex with human CD38 resolved at 1.53 Å resolution. A close-up view of the epitope highlights the interface between human CD38 and SAR650984-Fab, which involves mainly antibody heavy chain CDR loop H3 (yellow) and light chain CDR loops L1, L2 and L3 (green). For details, see the article by Deckert and colleagues on page 4574 of this issue.